South Korea Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The South Korean Oral Anti-Diabetic Drug Market Report is Segmented Into Drugs (Biguanides, Alpha-Glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides) and Geography. The Report Offers the Value (USD) and Volume (Units) for the Above Segments.

South Korea Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

South Korea Oral Anti-Diabetic Drug Industry Overview

The South Korean oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence, while the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.

South Korea Oral Anti-Diabetic Drug Market Leaders

  1. Eli Lilly and Company

  2. Astellas

  3. Sanofi

  4. Janseen

  5. Astrazeneca

  6. *Disclaimer: Major Players sorted in no particular order
South Korea Oral Anti-Diabetic Drug Market Concentration

South Korea Oral Anti-Diabetic Drug Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?